A cell engineering strategy to enhance the safety of stem cell therapies Academic Article uri icon

Overview

MeSH Major

  • Cell Engineering
  • Cell- and Tissue-Based Therapy
  • Induced Pluripotent Stem Cells

abstract

  • The long-term risk of malignancy associated with stem cell therapies is a significant concern in the clinical application of this exciting technology. We report a cancer-selective strategy to enhance the safety of stem cell therapies. Briefly, using a cell engineering approach, we show that aggressive cancers derived from human or murine induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are strikingly sensitive to temporary MYC blockade. On the other hand, differentiated tissues derived from human or mouse iPSCs can readily tolerate temporary MYC inactivation. In cancer cells, endogenous MYC is required to maintain the metabolic and epigenetic functions of the embryonic and cancer-specific pyruvate kinase M2 isoform (PKM2). In summary, our results implicate PKM2 in cancer's increased MYC dependence and indicate dominant MYC inhibition as a cancer-selective fail-safe for stem cell therapies.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4177332

Digital Object Identifier (DOI)

  • 10.1016/j.celrep.2014.08.039

PubMed ID

  • 25242333

Additional Document Info

start page

  • 1677

end page

  • 85

volume

  • 8

number

  • 6